var data={"title":"Calcitriol (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Calcitriol (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/770723?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=calcitriol-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Calcitriol (systemic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=calcitriol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcitriol (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561742\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rocaltrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561743\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Calcijex;</li>\n      <li>Calcitriol Injection;</li>\n      <li>Calcitriol-Odan;</li>\n      <li>Rocaltrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561748\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561796\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia in patients on chronic renal dialysis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Initial: 0.25 mcg daily; may increase dose by 0.25 mcg daily at 4- to 8-week intervals, up to 0.5 to 1 mcg daily; patients with normal or mildly decreased serum calcium levels may respond to 0.25 mcg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Initial: 1 to 2 mcg 3 times weekly approximately every other day. Adjust dose by 0.5 to 1 mcg at 2- to 4-week intervals; dosing range: 0.5 to 4 mcg 3 times weekly. Gradual dose reduction and discontinuation of therapy may be necessary as PTH levels decrease below target of (1.5 to 3 x ULN) in response to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia in hypoparathyroidism/pseudohypoparathyroidism:</b> Oral: Initial: 0.25 mcg daily (may adjust dose at 2- to 4-week intervals); range: 0.5 to 2 mcg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism associated with moderate-to-severe CKD in patients not yet on dialysis:</b> Oral: 0.25 mcg daily; may increase to 0.5 mcg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> KDIGO guidelines do not recommend routine vitamin D therapy (with vitamin D supplements or a vitamin D analog [eg, calcitriol]) for progressive or persistently elevated PTH concentrations in CKD patients (stages 3-5) not on dialysis in the absence of suspected/documented Vitamin D deficiency. Caution is advised to avoid hypercalcemia or elevated phosphate levels (KDIGO 2009; KDIGO 2012; Uhlig 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D-dependent rickets type 1/pseudovitamin D deficiency rickets (PDDR) (off-label use):</b> Oral: Initial: 0.5 mcg twice daily; subsequent dosing adjusted to maintain normal serum calcium and PTH levels; median dose after 2 years: 0.25 mcg daily (range: 0.1 to 0.5 mcg daily) (Edouard 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vitamin D-resistant rickets: </b> <i>Canadian labeling:</i> Oral: Initial: 0.25 mcg daily; may increase dose by 0.25 mcg daily at 2- to 4-week intervals if response is inadequate; discontinue use immediately for hypercalcemia and do not resume until calcium levels normalize.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561795\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=calcitriol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Calcitriol (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia in hypoparathyroidism/pseudohypoparathyroidism:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 5 years: Oral: Usual dosage range: 0.25 to 0.75 mcg once daily (may adjust dose at 2- to 4-week intervals)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism associated with moderate-to-severe CKD in patients not yet on dialysis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;3 years: Oral: Initial dose: 0.01 to 0.015 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561797\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Start at the lower end of the dosage range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561798\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\"> No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561799\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561814\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocaltrol: 0.25 mcg, 0.5 mcg [contains fd&amp;c yellow #6 (sunset yellow), methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mcg, 0.5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rocaltrol: 1 mcg/mL (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mcg/mL (15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561746\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561801\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May be administered as a bolus dose IV through the catheter at the end of hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May be administered without regard to food. Administer with meals to reduce GI problems.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561752\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Management of hypocalcemia in patients on chronic renal dialysis (oral, injection); management of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) not yet on dialysis (predialysis patients) (oral); management of hypocalcemia in patients with hypoparathyroidism and pseudohypoparathyroidism (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional uses (not in US labeling): Vitamin D-resistant rickets (oral)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561753\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Vitamin D-dependent rickets type I/pseudovitamin D deficiency rickets (PDDR)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561739\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Calcitriol may be confused with alfacalcidol, calcifediol, Calciferol, calcitonin, calcium carbonate, captopril, colestipol, paricalcitol, ropinirole</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dosage is expressed in mcg (micrograms), <b>not</b> mg (milligrams); rare cases of acute overdose have been reported</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561765\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Hypercalcemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Polydipsia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Apathy, drowsiness, hyperthermia, metallic taste, psychosis, sensory disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema, erythema multiforme, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Albuminuria, calcinosis, decreased libido, dehydration, growth suppression, hypercholesterolemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, constipation, pancreatitis, stomach pain, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hypercalciuria, nocturia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (mild)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Dystrophy, myalgia, ostealgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis, photophobia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Calcium nephrolithiasis, increased blood urea nitrogen, increased serum creatinine, polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Agitation, anaphylaxis, apprehension, hypermagnesemia, hyperphosphatemia, hypervitaminosis D, increased hematocrit, increased hemoglobin, increased neutrophils, increased serum alkaline phosphatase, insomnia, limb pain, lymphocytosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561762\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Oral, injection: Hypersensitivity to calcitriol or any component of the formulation; hypercalcemia, vitamin D toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Oral, injection: Hypersensitivity to calcitriol, vitamin D or its analogues or derivatives, or any component of the formulation or container; hypercalcemia, vitamin D toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561763\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease. Withhold pharmacologic doses of vitamin D and its derivatives during therapy to avoid the potential for hypercalcemia to develop. In addition, several months may be required for ergocalciferol levels to return to baseline in patients switching from ergocalciferol therapy to calcitriol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypercalcemia: Monitor calcium levels closely with initiation of therapy and with dose adjustments; discontinue use promptly in patients who develop hypercalcemia. Avoid abrupt dietary modifications (eg, increased intake of dairy products) which may lead to hypercalcemia; adjust calcium intake if indicated and maintain adequate hydration. Chronic hypercalcemia can result in generalized vascular and soft tissue calcification. Immobilized patients may be at a higher risk for hypercalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malabsorption syndrome: Use oral calcitriol with caution in patients with malabsorption syndromes; efficacy may be limited and/or response may be unpredictable. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use of calcitriol for the treatment of secondary hyperparathyroidism associated with CKD is not recommended in patients with rapidly worsening kidney function or in noncompliant patients. Increased serum phosphate levels in patients with renal failure may lead to ectopic calcification; the use of an aluminum-containing phosphate binder is recommended along with a low phosphate diet in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Calcium: Adequate dietary (supplemental) calcium is necessary for clinical response to vitamin D. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac glycosides: Use with caution in patients taking cardiac glycosides; digitalis toxicity is potentiated by hypercalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Magnesium-containing products: Concomitant use with magnesium-containing products such as antacids may lead to hypermagnesemia in patients receiving chronic renal dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Coconut oil: Products may contain coconut oil (capsule).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Palm seed oil: Products may contain palm seed oil (oral solution).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Some products may contain tartrazine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Calcium-phosphate product: Discontinue use immediately in adult patients with a calcium-phosphate product  (serum calcium times phosphorus) &gt;70 mg<sup>2</sup>/dL<sup>2</sup>; may resume therapy at decreased doses when levels are appropriate. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561772\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561769\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=107353&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May diminish the therapeutic effect of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcitriol (Systemic) may increase the serum concentration of Magnesium Salts.  Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Calcitriol (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561757\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561758\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in some animal reproduction studies. Maternal calcitriol may be detected in the fetal circulation. Mild hypercalcemia has been reported in a newborn following maternal use of calcitriol during pregnancy. Adverse effects on fetal development were not observed with use of calcitriol during pregnancy in women (N=9) with pseudovitamin D-dependent rickets. Doses were adjusted every 4 weeks to keep calcium concentrations within normal limits (Edouard 2011). If calcitriol is used for the management of hypoparathyroidism in pregnancy, dose adjustments may be needed as pregnancy progresses and again following delivery. Vitamin D and calcium levels should be monitored closely and kept in the lower normal range (Callies 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561761\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Low levels of calcitriol are found in breast milk (~2 pg/mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561800\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken without regard to food. Give with meals to reduce GI problems. Adequate calcium intake should be maintained during therapy; dietary phosphorous may need to be restricted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561806\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer&rsquo;s labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis patients: Serum calcium, phosphorus, magnesium, and alkaline phosphate monitored periodically</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypoparathyroid patients: Serum calcium, phosphorus, 24 hour urinary calcium monitored periodically</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Predialysis patients: Serum calcium, phosphorus, alkaline phosphatase, creatinine, and intact PTH, initially; then serum calcium, phosphorus, alkaline phosphatase, and creatinine monthly x 6 months, then periodically. Intact PTH should be monitored every 3-4 months. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">During titration periods (all patients), monitor serum calcium levels at least twice weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV therapy:  Serum calcium and phosphorus twice weekly (following initiation and during dosage adjustments) and periodically during therapy; periodic magnesium, alkaline phosphatase, 24 hour urinary calcium and phosphorous</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>KDIGO guidelines (2009):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Serum calcium, phosphorus, and PTH: CKD stages 3-5D:</i> Frequency of monitoring should be based on the presence and magnitude of abnormalities, as well as the rate of CKD progression. Reasonable intervals are:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD stage 3: Serum calcium and phosphorus, every 6 to 12 months; PTH: monitor based on baseline level and CKD progression</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD stage 4: Serum calcium and phosphorus every 3 to 6 months; PTH every 6 to 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CKD stage 5 (includes 5D): Serum calcium and phosphorus every 1 to 3 months; PTH every 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alkaline phosphatase:</i> CKD stages 4-5D: Monitor every 12 months or more frequently in the presence of increased PTH levels </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561782\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium: KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1 to 5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10 to 65 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1 to 6 pmol/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target ranges by stage of chronic kidney disease (KDIGO 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561780\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Calcitriol, the active form of vitamin D (1,25 hydroxyvitamin D<sub>3</sub>), binds to and activates the vitamin D receptor in kidney, parathyroid gland, intestine, and bone, stimulating intestinal calcium transport and absorption. It reduces PTH levels and improves calcium and phosphate homeostasis by stimulating bone resorption of calcium and increasing renal tubular reabsorption of calcium. Decreased renal conversion of vitamin D to its primary active metabolite (1,25 hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor, which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561783\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 2 hours; maximum effect: 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral, IV: 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 99.9% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Primarily to calcitroic acid and a lactone metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children 1.8-16 years undergoing peritoneal dialysis: 27.4 hours; Healthy adults: 5 to 8 hours; Hemodialysis: 16 to 22 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 3 to 6 hours; Hemodialysis: 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (27%); urine (7%, unchanged in 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Children 1.8 to 16 years undergoing peritoneal dialysis: 15.3 mL/hour/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28561819\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Calcitriol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mcg (100): $120.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mcg (100): $193.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Rocaltrol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mcg (30): $56.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mcg (100): $294.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcitriol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg/mL (1 mL): $9.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Calcitriol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg/mL (15 mL): $179.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rocaltrol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg/mL (15 mL): $235.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46329904\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Altrol (MX);</li>\n      <li>Bonkey (PK);</li>\n      <li>Cacare (TH);</li>\n      <li>Calciget (IN);</li>\n      <li>Calcijex (AE, BR, CN, HU, KW, MY, PH, PK, QA, SA, SG);</li>\n      <li>Calciraquiferol (AR);</li>\n      <li>Calcit (ID);</li>\n      <li>Calcit SG (LK, TH);</li>\n      <li>Caleobrol (CL, PY);</li>\n      <li>Caltril (BD);</li>\n      <li>Decostriol (DE, TH);</li>\n      <li>Dexiven (AR);</li>\n      <li>Dicaltrol (BD);</li>\n      <li>Improcal (BD);</li>\n      <li>Kolkatriol (ID);</li>\n      <li>Kosteo (AU);</li>\n      <li>Meditrol (LK, TH, VN);</li>\n      <li>Nafartol (MX);</li>\n      <li>Osteo D (BG, TH);</li>\n      <li>Osteocap (MY);</li>\n      <li>Osteodiol (HK);</li>\n      <li>Osteofem (ID);</li>\n      <li>Osteotriol (DE);</li>\n      <li>Ostriol (BD, BR);</li>\n      <li>Renatriol (CH, DE);</li>\n      <li>Renatrol (PH);</li>\n      <li>Rocaltrol (AE, AU, BB, BE, BG, BH, BR, CH, CL, CO, CU, CZ, DE, EC, EE, ES, FR, GB, HK, HR, HU, ID, IN, IT, JO, JP, LK, LU, LV, MT, MY, NL, NO, NZ, PE, PH, PK, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, UY, VE, VN);</li>\n      <li>Roical (SG);</li>\n      <li>Rolsical (IN);</li>\n      <li>Sical (AU);</li>\n      <li>Sigmatriol (UY);</li>\n      <li>Sitriol (AU);</li>\n      <li>Tirocal (MX);</li>\n      <li>Vitadia (UY);</li>\n      <li>Vitadol (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcijex (injection solution) [prescribing information]. North Chicago, IL: AbbVie Inc.; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcitriol (oral capsule) [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Callies F, Arlt W, Scholz HJ, et al, &ldquo;Management of Hypoparathyroidism During Pregnancy -- Report of Twelve Cases,&rdquo; <i>Eur J Endocrinol</i>, 1998, 139(3):284-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/9758437/pubmed\" target=\"_blank\" id=\"9758437\">9758437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20926527\"></a>Edouard T, Alos N, Chabot G, et al, &ldquo;Short- and Long-Term Outcome of Patients with Pseudo-Vitamin D Deficiency Rickets Treated with Calcitriol,&rdquo; <i>J Clin Endocrinol Metab</i>, 2011, 96(1):82-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/20926527/pubmed\" target=\"_blank\" id=\"20926527\">20926527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Letsou AP and Price LS, &ldquo;Health Aging and Nutrition: An Overview,&rdquo; <i>Clin Geriatr Med</i>, 1987, 3(2):253-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/3555761/pubmed\" target=\"_blank\" id=\"3555761\">3555761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocaltrol (calcitriol) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uhlig K, Berns JS, Kestenbaum B, et al, &ldquo;KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD), <i>Am J of Kidney Disease</i>, 2010, 55 (5):773-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/calcitriol-systemic-drug-information/abstract-text/20363541/pubmed\" target=\"_blank\" id=\"20363541\">20363541</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 107353 Version 48.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28561742\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F28561743\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28561748\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28561796\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F28561795\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28561797\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28561798\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28561799\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28561814\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28561746\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28561801\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28561752\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F28561753\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28561739\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28561765\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28561762\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28561763\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28561772\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28561769\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28561757\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28561758\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28561761\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F28561800\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28561806\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F28561782\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28561780\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28561783\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28561819\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46329904\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/107353|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=calcitriol-systemic-patient-drug-information\" class=\"drug drug_patient\">Calcitriol (systemic): Patient drug information</a></li><li><a href=\"topic.htm?path=calcitriol-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Calcitriol (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}